Welcome to the e-CCO Library!

DOP63: Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multi-centre, prospective, observational cohort study
Year: 2019
Source: ECCO '19 Copenhagen
Authors: G. Pineton de Chambrun1, B. Pariente2, P. Seksik3, R. Altwegg1, L. Vuitton4, C. Stefasnescu5, S. Nancey6, A. Aubourg7, M. Serrero8, L. Peyrin-Biroulet9, J. Filippi10, S. Viennot11, V. Abitbol12, M. Boualit13, A. Boureille14, J. Moreau15, A. Buisson16, X. Roblin17, M. Nachury2, M. Zappa18, J. Lambert19, Y. Bouhnik5, GETAID-MICA studygroup1
Created: Friday, 22 February 2019, 9:41 AM
Last Modified: Wednesday, 27 February 2019, 4:37 PM by ECCO Administrator
DOP63: Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Volkers, A.(1);Straatmijer, T.(1);Duijvestein, M.(2);Sales, A.(1);Levran, A.(1);van Schaik, F.(3);Jeroen, M.(4);Gecse, K.(1);Ponsioen, C.(1);Grootjans, J.(1);Hanzel, J.(1);Tack, G.(5);Jansen, J.(6);Hoentjen, F.(7);de Boer, N.(1);van der Marel, S.(8);Dijkstra, G.(9);Oldenburg, B.(3);Löwenberg, M.(1);van der meulen, A.(4);D'Haens, G.(1); on behalf of the IBD center of Amsterdam and the Dutch Initiative on Crohn and Colitis (ICC)
Created: Friday, 11 February 2022, 3:52 PM
DOP63: The Toronto IBD global endoscopic reporting (TIGER) score is well correlated with fecal calprotectin and IBD Disk in Ulcerative Colitis patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Zittan, E.(1,2);Steinhart, A.H.(3); Aran, H.(1);Milgrom, R.(3); Koifman, E.(1);Gralnek, I.M.(1); Zelber-Sagi, S.(2); Silverberg, M.S.(3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP63: Time Trends of Environmental and Socio-economical Factors in Patients with Inflammatory Bowel Disease over 40-year of Different Therapeutic Eras; results from a Population-based Cohort from Western Hungarian between 1977-2020, The Hygiene hypothesis revisited.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wetwittayakhlang, P.(1);Gonczi , L.(2);Lakatos , L.(3);Golovics , P.(4);Pandur , T.(5);David , G.(3);Erdelyi , Z.(3);Szita , I.(3);LakatosPhD, P.L.(6)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP64 Discovery of highly selective small-molecule oral inhibitors of integrin α4β7 for the treatment of inflammatory bowel diseases
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. WONG1, M. Bursavich2, N. Blanco1, A. Camblin1, L. Cappellucci1, R. Cohen1, D. Cui3, M. Krumpoch1, C. Zhong2, K. Hahn2, D. Lee3, B. Lippa2, F.Y. Lin4, A. Lugovsky5, M. McShea4, S. Mostafavi4, T. Moy1, A. Sullivan6, D. Troast2, L. Wang1, B. Rogers2

Created: Thursday, 30 January 2020, 10:12 AM
DOP64: Endoscopically injected allogeneic mesenchymal stromal cells alter the mucosal immune cell compartment in patients with ulcerative proctitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Ouboter, L.(1,2);Barnhoorn, M.(2);Plug, L.(2);van Pel, M.(1,3);Zwaginga, J.J.(4);Roelen, D.(1);Pascutti, F.(1);Koning, F.(1);Hawinkels, L.(2);Verspaget, H.(2);van der Meulen - de Jong, A.(2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP64: Minimal additional benefits in adding faecal haemoglobin to faecal calprotectin in predicting endoscopic disease activity in patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L-Y. Mak*1, L. Chen2, T. Tong2, S. Lau2, W-K. Leung2

Created: Friday, 22 February 2019, 9:41 AM
DOP64: Pathogenic RIPK1 Mutations Cause Infantile-onset IBD with Inflammatory and Fistulizing Features
Year: 2022
Source: ECCO'22
Authors: Sultan, M.(1);Millman, P.(2);McCourt, B.(3);Kol, N.(4);Lev, A.(5);Matar, M.(6);Barel, O.(4);Shamir, R.(6);Wilschanski, M.(2);Konnikova, L.(3);Somech, R.(5);Shouval, D.(6);
Created: Friday, 11 February 2022, 3:52 PM
DOP64: Utilising genomics to predict outcomes and delineate novel subgroups in inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ashton, J.(1,2)*;Cheng, G.(2);Stafford, I.(2);Beattie, R.M.(1);Ennis, S.(2);
Created: Friday, 14 July 2023, 10:43 AM
DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Steere1, J. Schmitz1, N. Powell2, R. Higgs1, K. Gottlieb1, Y. Liu1, B. Jia1, J.L. Tuttle3, W.J. Sandborn4, B.E. Sands5, V. Krishnan1

Created: Thursday, 30 January 2020, 10:12 AM
DOP65: Development and validation of the TUMMY-UC, a patient-reported outcome in pediatric Ulcerative Colitis: A multicenter prospective study
Year: 2022
Source: ECCO'22
Authors: Turner, D.(1);Marcovitch, L.(1);Focht, G.(1);Carmon, N.(1);Tersigni, C.(2);Ledder , O.(1);Lev Tzion, R.(1);Frost, K.(2);Church, P.C.(2);Baldassano, R.(3);Otley, A.(4);Kappelman, M.(5);Griffiths, A.(2);
Created: Friday, 11 February 2022, 3:52 PM
DOP65: Dietary therapy with the Crohn’s Disease exclusion diet induces sustained clinical and endoscopic remission in adults with Mild to Moderate Crohn's Disease: Results from the CDED-AD trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Yanai, H.(1,2);Levine , A.(2,3);Hirsch , A.(2,4);Sigall Boneh , R.(2,5);Kopylov , U.(2,6);Banai Eran, H.(1,2); Cohen, N.A.(2,4);Ron, Y.(2,4);Goren , I.(1,2);Leibovitzh, H.(1,2);Wardi , J.(2,7);Zittan, E.(8);Ziv-Baran , T.(2);Abramas, L.(5);Fliss-Isakov , N.(2,4);Raykhel, B.(1);Pfeffer Gik , T.(1,2);Dotan , I.(1,2);Maharshak, N.(2,4)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP65: T-cell derived TGFβ1 remodels the rectum mesenchyme in Crohn's Disease patients with perianal fistulizing disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gudiño, V.(1)*;Cho, J.W.(2);Corraliza, A.M.(1);Caballol, B.(3);Garrido-Trigo, A.(1);Masamunt, M.C.(3);Ordás, I.(3);Ricart, E.(3);Hemberg, M.(2);Panés, J.(3);Salas, A.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP65: The association of faecal calprotectin level and combined mucosal and transmural healing in patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Noh*1, E. H. Oh1, S. H. Park2,3, J. B. Lee4, J. Y. Kim1, J. C. Park1, J. Kim1, N. Ham1, E. M. Song1, S. H. Park1,3, S. W. Hwang1,3, D. H. Yang1, J. S. Byeon1, S. J. Myung1, S. K. Yang1,3, B. D. Ye1,3

Created: Friday, 22 February 2019, 9:41 AM
DOP66 A CEACAM5 small peptide restores the suppressive activity of CD8 + T cells in patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Roda PhD1, D. Dunkin2, C. Correale1, S. Vetrano1, F. Merlino3, L. Marinelli3, E. Novellino3, L. Mayer4, G. Yeretssian5,6, S. Danese1

Created: Thursday, 30 January 2020, 10:12 AM
DOP66: Disease course of Ulcerative proctitis in children: A population based study on behalf of the SIGENP IBD Group
Year: 2022
Source: ECCO'22
Authors: Martinelli, M.(1);Fedele, F.(1);Romano, C.(2);Aloi, M.(3);Lionetti, P.(4);Alvisi, P.(5);Panceri, R.(6);Bramuzzo, M.(7);Illiceto, M.(8);Bosa, L.(9);Norsa, L.(10);Pastore, M.(11);Graziano, F.(12);Arrigo, S.(13);Felici, E.(14);Gatti, S.(15);Fuoti, M.(16);Strisciuglio, C.(17);Dipasquale, V.(18);D'Arcangelo, G.(3);Scarallo, L.(4);Labriola, F.(5);Miele, E.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP66: Ileal resections from fibrotic-CD patients present microbiota dysbiosis, altered metabolomic profiles and metabolite-sensing GPCRs expression
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bauset, C.(1)*;Carda-Diéguez, M.(2);Buetas, E.(2);Lis-López, L.(1);Seco-Cervera, M.(3);Coll, S.(1);Ortiz-Masiá, D.(4);Calatayud, S.(5);Barrachina, M.D.(5);Mira, Á.(6);Cosín-Roger, J.(3);
Created: Friday, 14 July 2023, 10:43 AM
DOP66: Surveillance colonoscopies in ulcerative colitis: does it make a difference?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Hu*1, G. Nguyen2, J. Rangrej3, J. Marshall1, N. Narula1

Created: Friday, 22 February 2019, 9:41 AM
DOP66: The effect of exclusive enteral nutrition on circulating inflammatory protein levels in paediatric patients with Crohn’s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Pidoux , M.(1);Logan , M.(1);Milling , S.(2);Ijaz , U.Z.(3);Hansen , R.(4);Russell , R.K.(5);Gerasimidis , K.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP67 CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signalling pathway
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Shin1, N. Ha1, D. Bae1, Y.J. Lee1, Y.I. Choi1, K.H. Ryu1, G.S. Youn2, J. Park2

Created: Thursday, 30 January 2020, 10:12 AM